Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XCUR |
---|---|---|
09:32 ET | 1333 | 0.519 |
09:36 ET | 349 | 0.5481 |
09:38 ET | 495 | 0.5403 |
09:59 ET | 320 | 0.5481 |
10:30 ET | 200 | 0.53 |
10:33 ET | 746 | 0.5286 |
10:39 ET | 500 | 0.52 |
10:44 ET | 100 | 0.544367 |
10:48 ET | 102 | 0.53 |
11:18 ET | 200 | 0.5249 |
11:20 ET | 200 | 0.52 |
11:38 ET | 2306 | 0.518781 |
11:51 ET | 186 | 0.5188 |
11:58 ET | 630 | 0.515 |
12:02 ET | 5400 | 0.5188 |
12:03 ET | 2298 | 0.5206 |
12:07 ET | 117 | 0.5356 |
01:15 ET | 108 | 0.54 |
02:44 ET | 199 | 0.5206 |
03:50 ET | 310 | 0.515 |
03:59 ET | 112 | 0.515 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Exicure Inc | 4.7M | 0.4x | --- |
Predictive Technology Group Inc | 149.8K | 0.0x | --- |
SQZ Biotechnologies Co | 1.4M | 0.0x | --- |
Nabriva Therapeutics PLC | 320.0 | 0.0x | --- |
Agile Therapeutics Inc | 2.5M | 0.0x | --- |
Emmaus Life Sciences Inc | 4.9M | -1.1x | --- |
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.7M |
---|---|
Revenue (TTM) | $23.8M |
Shares Outstanding | 8.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $1.28 |
Book Value | $3.00 |
P/E Ratio | 0.4x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | 1.1x |
Operating Margin | 13.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.